Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and...
Brenart Eye Clinic, Yorkville, Illinois, United States
Chicago Cornea Consultants, Hoffman Estates, Illinois, United States
The Eye Institute of Utah, Salt Lake City, Utah, United States